MissionIR Articles

Today before the opening bell, Boston Therapeutics announced that it had signed a consulting agreement with Generosus Advisors, LLC and Fortified Management Group, LLC to market SugarDown® in the United States on a non-exclusive basis.…

Approximately 25.8 million Americans have diabetes, according to the National Diabetes Education Program, making the disease the seventh leading cause of death in the United States. To put it in monetary perspective, diabetes runs up…

Boston Therapeutics is a pharmaceutical company focused on the development, manufacturing, and commercialization of novel compounds based on complex carbohydrate chemistry to address unmet medical needs in diabetes. PAZ320 is an integral part of the…

Boston Therapeutics is developing a pipeline of novel compounds to address unmet medical needs in diabetes. The company’s current product pipeline is focused on developing and commercializing the therapeutic molecules PAZ320 for patients with diabetes;…

It’s turning out to be one of the biggest epidemic waves in American history, with estimated costs nationally jumping approximately 40% in just the past 5 years, to roughly $1/4 trillion annually. The epidemic is…

Boston Therapeutics is a pharmaceutical company using complex carbohydrate chemistry to advance its PAZ320 and IPOXYN drug candidates for the treatment of Type 2 diabetes. With 2013 under wraps, BTHE looks to have an exciting…

In the United States alone, an estimated 26 million people have Type 2 diabetes while another 80 million or so people are pre-diabetic. Recognizing that there are urgent, unfulfilled medical needs for both the pre-diabetic…

Boston Therapeutics is developing a pipeline of therapeutic molecules based on complex carbohydrate chemistry. This pipeline currently carries three compounds that are being fine-tuned and tested in hopes that each will become a commercialized therapeutic…

In a Seeking Alpha article published on Tuesday, November 26, 2013, Boston Therapeutics was highlighted as a biopharmaceutical company with promising investor potential. The article pointed to factors such as the company’s potentially “blockbuster” treatment…

Boston Therapeutics is a pharmaceutical company focused on the development and commercialization of novel compounds based on complex carbohydrate chemistry to address unmet medical needs. The company’s current product pipeline is focused on developing and…

Boston Therapeutics, a company focusing on the development of diabetes treatments using complex carbohydrate chemistry, continues to make progress in raising public awareness of its diabetes drug’s potential. The company announced in a news release…

Boston Therapeutics, a company focusing on the development of drugs using complex carbohydrate chemistry to address diabetes, reported in a news release today it is an exhibitor at the inaugural Obesity Week 2013 Conference in…

Boston Therapeutics announced it has begun enrolling patients in a Phase 2b Trial for its PAZ320 drug today. A total of 24 patients with type 2 diabetes currently being treated with metformin will be administered…

Boston Therapeutics today announces it will be making a presentation on a corporate update at the Livingston Securities Advanced and Nano Life Sciences Summit. The presentation is to be given by the President of Boston…

Boston Therapeutics today announces it has initiated a research study with the University of Minnesota on PAZ320, a complex carbohydrate-based drug designed to reduce the elevation of post-meal blood glucose by blocking the action of…

A recent BiotechStockTrader.com article (http://dtg.fm/SyR6), highlighting the unique and positive position that Boston Therapeutics now holds with regard to the multi-billion dollar diabetes drug industry, laid out the reasons why investors are starting to jump…

Boston Therapeutics, Inc. is a pharmaceutical company focused on the development and commercialization of novel compounds based on complex carbohydrate chemistry to address unmet medical needs. An IP portfolio solidifies the company’s position in the pharmaceutical…